


Collaborations Pharmaceuticals, Inc., Partners with Bausch + Lomb to Publish Research on Advancing Al Drug Development

RALEIGH, NC, UNITED STATES, October 7, 2025 /EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) has partnered with Bausch + Lomb to build and validate an array of artificial intelligence (AI) machine learning models with the goal of identifying new oral drugs that could reach the eye. The resulting paper, "MegaEye: Applying multiple machine learning approaches to identify oral compounds with ocular bioactivity," was recently published in Artificial Intelligence in the Life Sciences.

Oral administration of drugs to treat eye diseases has often failed in clinical trials. The ability of a molecule to reach a specific target in the eye is largely determined by whether its physicochemical properties permit



passage across the various ocular barriers that are relevant to the route of administration and the target location. CPI has been working with Bausch + Lomb to curate various public data for generating several computational models and a large language model called MegaEye, which was built to streamline the molecule repurposing and discovery process for ocular indications.

CPI identified over 100 oral drugs that could potentially be used for treating eye diseases, which were not previously widely known. CPI also used its models to search a very large natural product database to find potential repurposing candidates.

"Topical application is considered the easiest and safest route for delivering drugs to the eye, but oral dosing represents a non-invasive method that does not require sterile conditions and does not have compliance issues. Our work with Bausch + Lomb can help discover new molecules that

could represent future research projects for various eye diseases. We also illustrate how published data can be carefully curated and used to build these AI models, which represents a new opportunity for eye research," commented Sean Ekins, PhD., CEO of CPI.

Sean Ekins
Collaborations Pharmaceuticals, Inc.
+1 215-687-1320
email us here
Visit us on social media:
LinkedIn



This press release can be viewed online at: https://www.einpresswire.com/article/856039271

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.